Reduction of Atherosclerotic Plaques by Lysosomal Acid Lipase Supplementation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 1, 2004, Pages 147-154

  Du, Hong ^a   Schiavi, Susan ^b   Wan, Nick ^b   Levine, Mark ^b   Witte, David P ^a   Grabowski, Gregory A ^a,c  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b GENZYME CORPORATION   (United States)

^c Division of Human Genetics   (United States)

Author keywords

Atherosclerosis; Lesion; Lysosomal acid lipase; Mice

Indexed keywords

ACID LIPASE; CHOLESTEROL ESTER; LOW DENSITY LIPOPROTEIN RECEPTOR; MANNOSE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA VALVE; ARTICLE; ATHEROGENIC DIET; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME PURIFICATION; ENZYME REPLACEMENT; FAMILIAL HYPERCHOLESTEROLEMIA; FOAM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LYSOSOME; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PICHIA PASTORIS; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPLEEN; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; AORTIC DISEASES; AORTIC VALVE; ARTERIOSCLEROSIS; CHOLESTEROL ESTERS; CORONARY ARTERIOSCLEROSIS; DIET, ATHEROGENIC; INTESTINE, SMALL; LIPASE; LIVER; LYSOSOMES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; SPLEEN; TRIGLYCERIDES;

EID: 0347753259     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000107030.22053.1e     Document Type: Article

References (60)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138:S419-420.
3. Du H, Duanmu M, Witte D, Grabowski GA. Targeted disruption of the mouse lysosomal acid lipase gene: long-term survival with massive cholesteryl ester and triglyceride storage. Hum Mol Genet. 1998;7:1347-1354.
4. Lougheed M, Lum CM, Ling W, Suzuki H, Kodama T, Steinbrecher U. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II. J Biol Chem. 1997;272:12938-12944.
5. Ling W, Lougheed M, Suzuki H, Buchan A, Kodama T, Steinbrecher UP. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J Clin Invest. 1997;100:244-252.
6. Lysko PG, Weinstock J, Webb CL, Brawner ME, Elshourbagy NA. Identification of a small-molecule, nonpeptide macrophage scavenger receptor antagonist. J Pharmacol Exp Ther. 1999;289:1277-1285.
7. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
8. de Villiers WJ, Smart EJ. Macrophage scavenger receptors and foam cell formation. J Leukoc Biol. 1999;66:740-746.
9. Swarnakar S, Temel RE, Connelly MA, Azhar S, Williams DL. Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester. J Biol Chem. 1999;274:29733-29739.
10. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res. 1998;39:777-788.
11. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem. 1992;267:12420-12423.
12. Leppanen P, Luoma, J. S., Hofker, M. H., Havekes, L. M., Yla-Herttuala, S. Characterization of atherosclerotic lesion in apo E3-leiden transgenic mice. Atherosclerosis. 1998;136:147-152.
13. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARã. Cell. 1998;93:229-240.
14. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol. 1995;129:1403-1410.
15. Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL. Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver. J Biol Chem. 1990;265:21355-21362.
16. Rosenfeld ME, Khoo JC, Miller E, Parthasarathy S, Palinski W, Witztum JL. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest. 1991;87:90-99.
17. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
18. Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis. 1988;8:348-358.
19. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419-426.
20. Suits AG, Chait A, Aviram M, Heinecke JW. Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation. Proc Natl Acad Sci U S A. 1989;86:2713-2717.
21. Yancey PG, Jerome WG. Lysosomal cholesterol derived from mildly oxidized low density lipoprotein is resistant to efflux. J Lipid Res. 2001;42:317-327.
22. Jessup W, Mander EL, Dean RT. The intracellular storage and turnover of apolipoprotein B of oxidized LDL in macrophages. Biochim Biophys Acta. 1992;1126:167-177.
23. Jialal I, Chait A. Differences in the metabolism of oxidatively modified low density lipoprotein and acetylated low density lipoprotein by human endothelial cells: inhibition of cholesterol esterification by oxidatively modified low density lipoprotein. J Lipid Res. 1989;30:1561-1568.
24. Roma P, Catapano AL, Bertulli SM, Varesi L, Fumagalli R, Bernini F. Oxidized LDL increase free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. Biochem Biophys Res Commun. 1990;171:123-131.
25. Lougheed M, Zhang HF, Steinbrecher UP. Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages. J Biol Chem. 1991;266:14519-14525.
26. Tertov VV, Orekhov AN, Sobenin IA, Gabbasov ZA, Popov EG, Yaroslavov AA, Smirnov VN. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res. 1992;71:218-228.
27. Hoff HF, O'Neil J, Pepin JM, Cole TB. Macrophage uptake of cholesterol-containing particles derived from LDL and isolated from atherosclerotic lesions. Eur Heart J. 1990;11 Suppl E:105-115.
28. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes. 1988;37:550-557.
29. Lohse P, Chahrokh-Zadeh S, Seidel D. Human lysosomal acid lipase/cholesteryl ester hydrolase and human gastric lipase: identification of the catalytically active serine, aspartic acid, and histidine residues. J Lipid Res. 1997;38:892-903.
30. Assmann G, Seedorf U. Acid lipase deficiency: Wolman disease and cholesteryl eser storage disease. New York: McGraw-Hill; 2001.
31. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci U S A. 1993;90:11603-11607.
32. Kawabe Y, Honda M, Wada Y, Yazaki Y, Suzuki T, Ohba Y, Nabata H, Endo A, Matsumoto A, Itakura H, et al. Sterol mediated regulation of SREBP-1a, 1b, 1c and SREBP-2 in cultured human cells. Biochem Biophys Res Commun. 1994;202:1460-1467.
33. Wang X, Briggs MR, Hua X, Yokoyama C, Goldstein JL, Brown MS. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter, II: purification and characterization. J Biol Chem. 1993;268:14497-14504.
34. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell. 1994;77:53-62.
35. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARã promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
36. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T, et al. PPARã mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597-609.
37. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPARã is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611-617.
38. Heur M. Lysosomal regulation of gene expression, PhD thesis. Cincinnati: University of Cincinnati; 2002.
39. Du H, Schiavi S, Levine M, Mishra J, Heur M, Grabowski GA. Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet. 2001;10:1639-1648.
40. Gerdes LU, Gerdes, C., Klausen, I. C., and Faegeman, O. Generation of analytic plasma lipoprotein profiles using prepacked superose 6B columns. Clin. Chim. Acta. 1992;205:1-9.
41. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol. Chem. 1957;125:497-509.
42. Biggs HG, Erikson JM, Moorehead WR. A manual colorimetric assay of triglycerides in serium. Clin Chem. 1975;21:437-441.
43. Du H, Heur M, Duanmu M, Grabowski GA, Hui DY, Witte DP, Mishra J. Lysosomal acid lipase-deficient mice: depletion of white and brown fat, severe hepatosplenomegaly, and shortened life span. J Lipid Res. 2001;42:489-500.
44. Rudel LL, Morris MD. Determination of cholesterol using O-phthalaldehyde. J lipid Res. 1973;14:164-366.
45. Du H, Sheriff S, Bezerra J, Leonova T, Grabowski GA. Molecular and enzymatic analyses of lysosomal acid lipase in cholesteryl ester storage disease. Mol Genet Metab. 1998;64:126-134.
46. Sheriff S, Du H, Grabowski GA. Characterization of lysosomal acid lipase by site-directed mutagenesis and heterologous expression. J Biol Chem. 1995;270:27766-27772.
47. Peters TJ, De Duve C. Lysosomes of the arterial wall, II: subcellular fractionation of aortic cells from rabbits with experimental atheroma. Exp Mol Pathol. 1974;20:228-256.
48. Guyton JR, Klemp KF. Development of the atherosclerotic core region: chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb. 1994;14:1305-1314.
49. Smith EB, Slater RS, Chu PK. The lipids in raised fatty and fibrous lesions in human aorta: a comparison of the changes at different stages of development. J Atheroscler Res. 1968;8:399-419.
50. Smith EB, Slater RS. Relationship between plasma lipids and arerial tissue lipids. Nutr Metab. 1973;15:17-26.
51. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-ã is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
52. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor (PPAR ã) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66:733-739.
53. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARã: differentiation-dependent peroxisomal proliferator-activated receptor ã (PPARã) expression and reduction of MMP-9 activity through PPARã activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17-23.
54. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor ã ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
55. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR ã-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
56. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-á and PPAR-ã activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
57. Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. J Biol Chem. 2000;275:23807-23813.
58. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem. 2001;276:42468-42476.
59. Maehira F, Harada K, Shimoji J, Miyagi I, Nakano M. Age-related changes in the activation of aortic cholesteryl ester hydrolases by protein kinase in rats. Bioch. Biophy. Acta. 1998;1389:197-205.
60. Hoppe G, O'Neil, J., Hoff, H. F. Inactivation of lysosomal protease by oxidized low density lipoprotein is partially responsible for its poor degradation by mouse peritoneal macrophages. J. Clin. Invest. 1994;94:1506-1512.